TR201900708T4 - HIV veya AIDS'in tedavisine yönelik bileşim. - Google Patents
HIV veya AIDS'in tedavisine yönelik bileşim. Download PDFInfo
- Publication number
- TR201900708T4 TR201900708T4 TR2019/00708T TR201900708T TR201900708T4 TR 201900708 T4 TR201900708 T4 TR 201900708T4 TR 2019/00708 T TR2019/00708 T TR 2019/00708T TR 201900708 T TR201900708 T TR 201900708T TR 201900708 T4 TR201900708 T4 TR 201900708T4
- Authority
- TR
- Turkey
- Prior art keywords
- vitamin
- composition
- aids
- 200mcg
- selenium
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 2
- 229930003268 Vitamin C Natural products 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000011669 selenium Substances 0.000 abstract 2
- 229910052711 selenium Inorganic materials 0.000 abstract 2
- 229940088594 vitamin Drugs 0.000 abstract 2
- 229930003231 vitamin Natural products 0.000 abstract 2
- 235000013343 vitamin Nutrition 0.000 abstract 2
- 239000011782 vitamin Substances 0.000 abstract 2
- 235000019155 vitamin A Nutrition 0.000 abstract 2
- 239000011719 vitamin A Substances 0.000 abstract 2
- 235000019154 vitamin C Nutrition 0.000 abstract 2
- 239000011718 vitamin C Substances 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 229940045997 vitamin a Drugs 0.000 abstract 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 229930003571 Vitamin B5 Natural products 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract 1
- 235000013734 beta-carotene Nutrition 0.000 abstract 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract 1
- 239000011648 beta-carotene Substances 0.000 abstract 1
- 229960002747 betacarotene Drugs 0.000 abstract 1
- 238000010170 biological method Methods 0.000 abstract 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 abstract 1
- 229960002079 calcium pantothenate Drugs 0.000 abstract 1
- 229910052804 chromium Inorganic materials 0.000 abstract 1
- 239000011651 chromium Substances 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 235000009492 vitamin B5 Nutrition 0.000 abstract 1
- 239000011675 vitamin B5 Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A Vitamini, C Vitamini, E Vitamini ve 20 mcg'dan fazla Selenyumun bir günlük ortalama dozajını içeren herhangi bir biyolojik yöntem aracılığıyla, herhangi bir formda, kombine, sıralı veya eşzamanlı uygulamaya yönelik, HIV virüsü veya AIDS'in tedavisinde kullanıma yönelik bir farmasötik bileşimdir. Optimal düzenlemesinde bileşim, yaklaşık 1500mcg A Vitamini, 6mg Betakaroten, 15mg B1 Vitamini, 10mg B2 Vitamini, 20mg B5 Vitamini, 20mg B6 Vitamin, 15mcg B12 Vitamin, 500mcg Folik asit, 300mg C Vitamini, 10mcg D Vitamini, 120mg E Vitamini, 95mcg K Vitamini, 6mg Demir, 100mg Magnezyum, 15mg Çinko, 200mcg İyodin, 2mg Bakır, 4mg Manganez, 200mcg Selenyum, 100mcg Krom, 40mg Sistin, 40mg Metiyonin ve 30mg Bioflavonoid?in ortalama günlük dozajlarından oluşur.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0300078A GB2396809A (en) | 2003-01-03 | 2003-01-03 | Composition for the treatment of HIV and AIDS |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201900708T4 true TR201900708T4 (tr) | 2019-02-21 |
Family
ID=9950630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/00708T TR201900708T4 (tr) | 2003-01-03 | 2004-12-30 | HIV veya AIDS'in tedavisine yönelik bileşim. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1590046B1 (tr) |
AU (1) | AU2003295163A1 (tr) |
DK (1) | DK1590046T3 (tr) |
ES (1) | ES2707386T3 (tr) |
GB (1) | GB2396809A (tr) |
PT (1) | PT1590046T (tr) |
TR (1) | TR201900708T4 (tr) |
WO (1) | WO2004060487A2 (tr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1643865A1 (en) * | 2003-06-04 | 2006-04-12 | Willem Jacob Serfontein | Nutritional compositions and use thereof |
EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
JPWO2018079573A1 (ja) * | 2016-10-26 | 2019-09-19 | 味の素株式会社 | 消化管における吸収低下の改善用組成物、および消化管における吸収の促進用組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
FR2718353B3 (fr) * | 1994-04-11 | 1996-06-28 | Jean Berque | Compositions pharmaceutiques à base de produits biologiques atoxiques destinées à la protection locale des muqueuses génitales et rectales. |
WO1998018491A1 (en) * | 1996-10-28 | 1998-05-07 | BURGSTINER, Jacqueline, Cook | Methods and compositions for dietary supplementation |
US5985339A (en) * | 1996-11-22 | 1999-11-16 | Kamarei; A. Reza | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products |
US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
FR2792201B1 (fr) * | 1999-04-15 | 2001-11-02 | Donatien Mavoungou | Procede du renforcement immunitaire et du developpement d'un transporteur lipidique pour une therapie genique anti-vih et anti-bacterienne |
-
2003
- 2003-01-03 GB GB0300078A patent/GB2396809A/en not_active Withdrawn
- 2003-12-30 DK DK03786164.8T patent/DK1590046T3/en active
- 2003-12-30 EP EP03786164.8A patent/EP1590046B1/en not_active Expired - Lifetime
- 2003-12-30 WO PCT/GB2003/005688 patent/WO2004060487A2/en not_active Application Discontinuation
- 2003-12-30 AU AU2003295163A patent/AU2003295163A1/en not_active Abandoned
- 2003-12-30 ES ES03786164T patent/ES2707386T3/es not_active Expired - Lifetime
- 2003-12-30 PT PT03786164T patent/PT1590046T/pt unknown
-
2004
- 2004-12-30 TR TR2019/00708T patent/TR201900708T4/tr unknown
Also Published As
Publication number | Publication date |
---|---|
ES2707386T3 (es) | 2019-04-03 |
GB2396809A (en) | 2004-07-07 |
PT1590046T (pt) | 2019-02-01 |
AU2003295163A1 (en) | 2004-07-29 |
DK1590046T3 (en) | 2019-02-18 |
EP1590046B1 (en) | 2018-10-31 |
WO2004060487A3 (en) | 2004-08-26 |
WO2004060487A2 (en) | 2004-07-22 |
EP1590046A2 (en) | 2005-11-02 |
GB0300078D0 (en) | 2003-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0942720B1 (en) | Use of metal complexes to treat gastrointestinal infections | |
BR9814378A (pt) | Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase | |
WO2009115769A4 (en) | Composition for hair, skin and nail health maintenance | |
ATE247953T1 (de) | Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure | |
RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
TR201900708T4 (tr) | HIV veya AIDS'in tedavisine yönelik bileşim. | |
HUP0303466A2 (hu) | Eljárás és adagolási forma tumorok tegafur, uracil, folinsav, paclitaxel és carboplatin beadásával való kezelésére | |
CA2559239A1 (en) | Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night | |
MA29722B1 (fr) | Schema posologique pour le prasugrel | |
RU2000132310A (ru) | Применение продуктов на основе магния для лечения или профилактики опухолевых и аутоиммунных заболеваний | |
MXPA04001933A (es) | Composicion farmaceutica que comprende lumiracoxib. | |
UA32457C2 (uk) | Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм | |
BR0213449A (pt) | Comprimido mastigável contendo lisina | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
CA2385755A1 (en) | Prevention of colorectal cancer | |
TAKAHASHI et al. | Studies on Glugea Infection of the Ayu, Plecoglossus altivelis—II. On the Prevention and Treatment-(1) Fumagillin Efficacy as a Treatment | |
RU2727598C2 (ru) | Способ лечения больных раком с тяжелой почечной недостаточностью | |
Motoya et al. | Effects of ascorbic acid on interactions between ciprofloxacin and ferrous sulphate, sodium ferrous citrate or ferric pyrophosphate, in mice | |
ATE369135T1 (de) | Behandlung von depression und zusammensetzungen dazu | |
US20030198695A1 (en) | Herbo-mineral composition | |
KR100405918B1 (en) | Pharmaceutical composition for treatment of cancer containing p43 protein and paclitaxel | |
RU2018133603A (ru) | Пероральная дозированная форма двух изомеров кломифена и способ ее использования для лечения вторичного гипогонадизма и минимизации побочных эффектов лекарственного препарата у мужчин | |
US20050220899A1 (en) | Use of cisplatin in combination with folic acid for increasing cisplatin efficacy | |
TH79600A (th) | รูปแบบยาของแข็งที่ให้ทางปากที่มีขนาดของเอสตราไดออลต่ำ | |
IT1320772B1 (it) | Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale |